Skip to main content
AUTOBIO DIAGNOSTICS CO., LTD logo

AUTOBIO DIAGNOSTICS CO., LTD — Investor Relations & Filings

Ticker · 603658 ISIN · CNE100002GC4 LEI · 300300HTZSCUCA32U369 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,291 across all filing types
Latest filing 2020-02-26 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 603658

About AUTOBIO DIAGNOSTICS CO., LTD

https://en.autobio.com.cn/

Autobio Diagnostics Co., Ltd. specializes in the research, development, manufacturing, and distribution of comprehensive in vitro diagnostic (IVD) solutions. The company offers an extensive portfolio of products across multiple clinical disciplines, including immunoassay, microbiology, and molecular diagnostics. Key offerings include high-throughput chemiluminescence immunoassay (CLIA) systems, enzyme-linked immunosorbent assay (ELISA) kits, and automated microbiology platforms for blood culture and microbial identification. Autobio also provides integrated laboratory automation systems designed to enhance diagnostic efficiency and accuracy. By focusing on technological innovation and quality, the company serves clinical laboratories, hospitals, and medical institutions worldwide, supporting the detection of infectious diseases, oncology markers, and various metabolic disorders.

Recent filings

Filing Released Lang Actions
关于全资子公司通过高新技术企业重新认定的公告
Regulatory Filings Classification · 95% confidence The document is a short announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding its wholly-owned subsidiary receiving a renewed High-Tech Enterprise Certificate. It mentions tax benefits and certificate validity but contains no financial statements, detailed financial data, or report attachments. The document is brief (553 characters) and serves as a regulatory announcement about a certification status update rather than a financial report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2020-02-26 Chinese
使用闲置自有资金进行现金管理的进展公告
Capital/Financing Update Classification · 95% confidence The document is a detailed announcement from Zhengzhou Antu Bioengineering Co., Ltd. regarding the progress of cash management using idle self-owned funds. It includes specifics about entrusted financial products, amounts, risk control, contract terms, and the impact on the company. The document is not a financial report like an annual or interim report, nor is it a regulatory certification or a brief announcement. It is a progress update on capital management activities, specifically about the use of idle funds for cash management and investment in financial products. This fits best under the category of Capital/Financing Update (CAP), as it provides detailed information on the company's financing activities related to cash management and investment of idle funds. The document length (6773 characters) and content support this classification with high confidence.
2020-02-25 Chinese
联合信用评级有限公司关于郑州安图生物工程股份有限公司主体长期信用等级及“安图转债”终止跟踪评级的通知
Regulatory Filings
2020-02-21 Chinese
关于取得医疗器械注册证书的公告
Regulatory Filings Classification · 95% confidence The document is a company announcement regarding the receipt of medical device registration certificates from the National Medical Products Administration. It details the product names, registration numbers, intended uses, and R&D investment amounts. The document discusses the impact on company performance and includes a risk warning. It is a regulatory announcement about product certification and does not contain financial statements, earnings data, or management changes. The document length is short (1349 characters) and it is an official announcement rather than a report or detailed financial filing. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement that does not fit other specific categories.
2020-02-20 Chinese
关于“安图转债”赎回结果暨股份变动公告
Share Issue/Capital Change Classification · 95% confidence The document is an official announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the redemption results of its convertible bonds ('Antu Convertible Bonds') and the related changes in shareholding. It details the redemption quantity, price, payment date, and the delisting of the convertible bonds from the Shanghai Stock Exchange. The document includes specific financial figures related to the redemption and the impact on the company's share capital. The content is focused on the redemption event and the resulting share capital changes, not a full financial report or earnings release. It is not a report publication announcement since it contains substantive details about the redemption and share changes. This fits the category of a Share Issue/Capital Change announcement, as it involves changes in the company's capital structure due to bond redemption and conversion into shares.
2020-02-19 Chinese
关于“安图转债”赎回的第五次提示性公告
Delisting Announcement Classification · 95% confidence The document is a formal announcement from Zhengzhou Antu Biological Engineering Co., Ltd. regarding the fifth reminder about the redemption of its convertible bonds (referred to as 'Antu Convertible Bonds'). It details the redemption date, redemption price, procedures, and related tax information. It also mentions that after the redemption, the convertible bonds will be delisted from the Shanghai Stock Exchange. The document is not a financial report, earnings release, or management discussion but a specific notice about bond redemption and related trading cessation and delisting. This fits the category of a Delisting Announcement (DLST) because it announces the upcoming removal of the convertible bonds from the exchange following redemption. The document length is 3204 characters, which is consistent with an announcement rather than a full report. Therefore, the correct classification is DLST with high confidence.
2020-02-17 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.